Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
•
Primary Care
Are there data to support the use of herbal supplements, prebiotics, or probiotics in the management of SIBO?
Related Questions
Is there a particular prokinetic agent that you recommend if a patient has failed both PPI and TCA in the treatment of suspected functional dyspepsia?
What therapies have you found most effective for JAK-induced/associated acne (JAKcne)?
Do you prefer formal testing to establish a diagnosis of SIBO/IMO over empiric treatment?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
How do you determine whether to limit volume removal during therapeutic paracentesis in a patient without acute or chronic kidney disease?
Do you avoid the use of GLP-1 R agonist therapy for treatment of obesity in patients with known gastroparesis?
How do you practically approach a tailored elimination diet in young patients with numerous food impactions and esophageal strictures who are intermittently compliant with PPI or topical steroids?
In patients with longstanding UC or Crohn's colitis, would you extend the interval of surveillance colonoscopy to longer than 3 years if they have had little inflammatory disease over the years and no other factors to increase their risk (ie, history of polyps, history of dysplasia, or family history)?
How would you manage a patient taking a GLP-1 agonist for weight loss who continues to have symptoms (i.e., nausea, vomiting) related to reduced GI motility despite dose adjustments?
